Eli Lilly and Company: Endocrine System Diseases trials

The registry lists 13 Endocrine System Diseases studies with Eli Lilly and Company as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 3Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingRecruitingNCT07613307Phase 3
• A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 DiabetesCompletedNCT05691712Phase 3Results posted
• A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or BothCompletedNCT05260021Phase 3Results posted
• A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesCompletedNCT04809220Phase 3Results posted
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesCompletedNCT04255433Phase 3Results posted
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskCompletedNCT03730662Phase 3Results posted
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
• A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese ParticipantsCompletedNCT06869018Phase 1
• Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)CompletedNCT06354660Phase 3
• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Active, not recruitingNCT06297603Phase 3
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Active, not recruitingNCT06260722Phase 3
• A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityActive, not recruitingNCT06037252Phase 2